Atara Biotherapeutics
ATRA
124 hedge funds and large institutions have $1.71B invested in Atara Biotherapeutics in 2018 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 60 increasing their positions, 29 reducing their positions, and 10 closing their positions.
107% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 29
100% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 10
18% more call options, than puts
Call options by funds: $14.6M | Put options by funds: $12.3M
9% more funds holding
Funds holding: 114 → 124 (+10)
1% more capital invested
Capital invested by funds: $1.7B → $1.71B (+$8.86M)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.27% less ownership
Funds ownership: 4.49% → 4.23% (-0.27%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$37.8M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$34.4M |
| 3 |
BlackRock
New York
|
+$22.4M |
| 4 |
Wells Fargo
San Francisco,
California
|
+$14.3M |
| 5 |
Goldman Sachs
New York
|
+$10.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
PointState Capital
New York
|
-$11.6M |
| 2 |
AG
Artal Group
Luxembourg
|
-$10.7M |
| 3 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$7.69M |
| 4 |
Jennison Associates
New York
|
-$7.05M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$5.09M |
ATRA Hedge Fund Activity: Q2 2018 in Review
124 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Atara Biotherapeutics (ATRA) for Q2 2018, worth a combined $1.71B — up 0.52% from $1.7B a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new ATRA positions and 10 closed out — a net gain of 10 holders — while 60 added to existing stakes and 29 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $37.8M. The largest seller was PointState Capital, exiting entirely with an estimated $11.6M sold.
- 124 institutional investors held Atara Biotherapeutics (ATRA) as of Q2 2018, up from 114 in Q1 2018.
- Funds reported $1.71B of Atara Biotherapeutics stock for Q2 2018, up 0.52% quarter-over-quarter.
- 20 funds opened new Atara Biotherapeutics positions in Q2 2018 and 10 closed out, a net change of +10 holders.
- The largest Atara Biotherapeutics buyer in Q2 2018 was JP Morgan Chase, an estimated $37.8M added.
- The largest Atara Biotherapeutics seller in Q2 2018 was PointState Capital, an estimated $11.6M sold.
Based on aggregated 13F filings for Q2 2018.